Structure-Guided Deimmunization of Therapeutic Proteins

Therapeutic proteins continue to yield revolutionary new treatments for a growing spectrum of human disease, but the development of these powerful drugs requires solving a unique set of challenges. For instance, it is increasingly apparent that mitigating potential anti-therapeutic immune responses, driven by molecular recognition of a therapeutic protein's peptide fragments, may be best accomplished early in the drug development process. One may eliminate immunogenic peptide fragments by mutating the cognate amino acid sequences, but deimmunizing mutations are constrained by the need for a folded, stable, and functional protein structure. These two concerns may be competing, as the mutations that are best at reducing immunogenicity often involve amino acids that are substantially different physicochemically. We develop a novel approach, called EpiSweep, that simultaneously optimizes both concerns. Our algorithm identifies sets of mutations making such Pareto optimal trade-offs between structure and immunogenicity, embodied by a molecular mechanics energy function and a T-cell epitope predictor, respectively. EpiSweep integrates structure-based protein design, sequence-based protein deimmunization, and algorithms for finding the Pareto frontier of a design space. While structure-based protein design is NP-hard, we employ integer programming techniques that are efficient in practice. Furthermore, EpiSweep only invokes the optimizer once per identified Pareto optimal design. We show that EpiSweep designs of regions of the therapeutics erythropoietin and staphylokinase are predicted to outperform previous experimental efforts. We also demonstrate EpiSweep's capacity for deimmunization of the entire proteins, case analyses involving dozens of predicted epitopes, and tens of thousands of unique side-chain interactions. Ultimately, Epi-Sweep is a powerful protein design tool that guides the protein engineer toward the most promising immunotolerant biotherapeutic candidates.

[1]  Chris Bailey-Kellogg,et al.  A divide‐and‐conquer approach to determine the Pareto frontier for optimization of protein engineering experiments , 2012, Proteins.

[2]  Chris Bailey-Kellogg,et al.  Open Access Methodology Article Optimization Algorithms for Functional Deimmunization of Therapeutic Proteins , 2022 .

[3]  Marc De Maeyer,et al.  Elimination of a Human T-cell Region in Staphylokinase by T-cell Screening and Computer Modeling , 2002, Thrombosis and Haemostasis.

[4]  R. Goldstein.  Efficient rotamer elimination applied to protein side-chains and related spin glasses. , 1994, Biophysical journal.

[5]  Huub Schellekens,et al.  Bioequivalence and the immunogenicity of biopharmaceuticals , 2002, Nature Reviews Drug Discovery.

[6]  Huub Schellekens,et al.  Immunogenicity of biopharmaceuticals. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  David E. Golan,et al.  Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.

[8]  Chris Bailey-Kellogg,et al.  Optimization of Combinatorial Mutagenesis , 2011, RECOMB.

[9]  Bruce Randall Donald,et al.  A Novel Minimized Dead-End Elimination Criterion and Its Application to Protein Redesign in a Hybrid Scoring and Search Algorithm for Computing Partition Functions over Molecular Ensembles , 2006, RECOMB.

[10]  John Sidney,et al.  Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity , 2005, The Journal of Immunology.

[11]  P Argos,et al.  Oligopeptide biases in protein sequences and their use in predicting protein coding regions in nucleotide sequences , 1988, Proteins.

[12]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[13]  George I. Makhatadze,et al.  Rational stabilization of enzymes by computational redesign of surface charge–charge interactions , 2009, Proceedings of the National Academy of Sciences.

[14]  A. Fersht,et al.  Contribution of a proline residue and a salt bridge to the stability of a type I reverse turn in chymotrypsin inhibitor-2. , 1994, Protein engineering.

[15]  J. Foote,et al.  Immunogenicity of engineered antibodies. , 2005, Methods.

[16]  W. Martin,et al.  De-immunization of therapeutic proteins by T-cell epitope modification. , 2005, Developments in biologicals.

[17]  Leonard Moise,et al.  Prediction of immunogenicity for therapeutic proteins: state of the art. , 2007, Current opinion in drug discovery & development.

[18]  John Sidney,et al.  A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..

[19]  Gevorg Grigoryan,et al.  Design of protein-interaction specificity affords selective bZIP-binding peptides , 2009, Nature.

[20]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.

[21]  Chris Bailey-Kellogg,et al.  Algorithms for Joint Optimization of Stability and Diversity in Planning Combinatorial Libraries of Chimeric Proteins , 2008, RECOMB.

[22]  Huan-Xiang Zhou,et al.  Salt Bridges Stabilize the Folded Structure of Barnase , 2001 .

[23]  Chris Bailey-Kellogg,et al.  Optimization of Therapeutic proteins to Delete T-Cell epitopes while Maintaining Beneficial Residue Interactions , 2011, J. Bioinform. Comput. Biol..

[24]  D. Baker,et al.  Native protein sequences are close to optimal for their structures. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[26]  Amy C. Anderson,et al.  Computational structure-based redesign of enzyme activity , 2009, Proceedings of the National Academy of Sciences.

[27]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..

[28]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[29]  Anne S De Groot,et al.  Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. , 2009, Clinical immunology.

[30]  A. Mustafa,et al.  ProPred analysis and experimental evaluation of promiscuous T-cell epitopes of three major secreted antigens of Mycobacterium tuberculosis. , 2006, Tuberculosis.

[31]  Adrian A Canutescu,et al.  Access the most recent version at doi: 10.1110/ps.03154503 References , 2003 .

[32]  Johan Desmet,et al.  The dead-end elimination theorem and its use in protein side-chain positioning , 1992, Nature.

[33]  Niles A Pierce,et al.  Protein design is NP-hard. , 2002, Protein engineering.

[34]  Chris Bailey-Kellogg,et al.  Design and analysis of immune-evading enzymes for ADEPT therapy. , 2012, Protein engineering, design & selection : PEDS.

[35]  Bruce Randall Donald,et al.  A novel ensemble-based scoring and search algorithm for protein redesign, and its application to modify the substrate specificity of the gramicidin synthetase A phenylalanine adenylation enzyme , 2004, RECOMB.

[36]  Mona Singh,et al.  Solving and analyzing side-chain positioning problems using linear and integer programming , 2005, Bioinform..

[37]  T. Baglin,et al.  Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII , 2005, Journal of thrombosis and haemostasis : JTH.

[38]  S. L. Mayo,et al.  De novo protein design: fully automated sequence selection. , 1997, Science.

[39]  G. Murdaca,et al.  Immunogenicity of erythropoietin and other growth factors. , 2002, Reviews in clinical and experimental hematology.

[40]  R. Alexander,et al.  Identification of HLA‐DRB1*1501‐restricted T‐cell epitopes from human prostatic acid phosphatase , 2007, The Prostate.

[41]  Anil K Ghosh,et al.  Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen , 2007, Proceedings of the National Academy of Sciences.